BMS reports Opdivo survival benefit

Bristol-Myers Squibb Co. (NYSE:BMY) said patients receiving its Opdivo nivolumab had a five-year overall survival (OS) rate of 34% in the Phase Ib CA209-003 trial to treat advanced melanoma. BMS said the data represent the longest survival follow-up conducted for an anti- PD-1 therapy.

Among 107 pre-treated patients, median OS was 17.3 months (95% CI: 12.5, 37.8) across all Opdivo doses. Data were presented at the American Association for Cancer Research (AACR) meeting in New Orleans. ...